Drugmaker Pfizer hid that one of its powerful anti-inflammatory drugs for rheumatoid arthritis therapy, Enbrel, reduced the risk of Alzheimer’s disease by 64%, according to a report by the Washington Post.

Partners HealthCare, a Boston-based health system, has backed out of its planned acquisition of Care New England

Thomas Frieden, MD, former director of the CDC, pleaded guilty to a disorderly conduct violation after he was arrested last year for sexual misconduct, the Associated Press reported.

Whether or not its pending $68 billion purchase of Aetna gets finalized, CVS Health will pump big bucks into broadening its menu of healthcare services and personalizing them for consumers. And a key component of its plan is a data-analytics strategy steeped in AI.

UCLA Health is synthesizing vast amounts of data by deploying new Microsoft cloud computing services, Microsoft Azure, that will speed up medical discoveries and improve patient care.

Amid an ongoing court review of its $69 billion merger with health insurer Aetna, CVS Health isn’t slowing down in its plans to expand, according to executives who spoke at the company’s investor day on June 4.

Brand-name drugs are likely to keep rising in price, even though the top-selling ones have been available for years and have already seen their costs skyrocket, according to a new study published in JAMA.

Tempus, a Chicago-based precision medicine company that uses machine learning, genomic sequencing and other AI innovations, has raised $200 million in a series F funding round, the company announced.